SCHEMBL24879683

SCHEMBL24879683

CCOCC(=O)Nc1c(Cl)nc2ccccc2c1NCC(C)O

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.44
ALDH1A1 P00352 2/20 0.44
RAB9A P51151 2/20 0.44
NPC1 O15118 1/20 0.44
MAPK1 P28482 1/20 0.44
HTT P42858 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
POLB P06746 2/20 0.43
GLA P06280 2/20 0.43
TSHR P16473 1/20 0.41
TOP2A P11388 3/20 0.40
GAA P10253 3/20 0.40
APP P05067 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
P2RX7 Q99572 1/20 0.39
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14950200 0.86 TOP2A (0.48) KDM4EALDH1A1RAB9ANPC1MAPK1
SCHEMBL1457271 0.84 KDM4E (0.45) KDM4EALDH1A1RAB9ANPC1MAPK1
SCHEMBL5800900 0.83 TOP2A (0.47) KDM4EALDH1A1RAB9ANPC1MAPK1
SCHEMBL7637380 0.83 KDM4E (0.44) KDM4EALDH1A1RAB9ANPC1MAPK1
SCHEMBL8571971 0.82 KDM4E (0.43) KDM4EALDH1A1RAB9ANPC1MAPK1
SCHEMBL1457334 0.80 TOP2A (0.45) KDM4EALDH1A1RAB9ANPC1MAPK1
SCHEMBL1456618 0.79 BCHE (0.46) KDM4EALDH1A1RAB9ANPC1MAPK1
SCHEMBL7643118 0.76 MEN1 (0.42) KDM4EALDH1A1RAB9ASMN1; SMN2POLB
SCHEMBL1457309 0.74 ACP1 (0.37) KDM4EALDH1A1RAB9ANPC1MAPK1
SCHEMBL24879684 0.74 POLB (0.40) KDM4EALDH1A1RAB9ASMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230008368-A1 IMIDAZOQUINOLINE SUBSTITUTED PHOSPHORIC ESTER AGONIST, AND PREPARATION THEREFOR AND APPLICATION THEREOF SUZHOU ZELGEN BIOPHARMACEUTICALS CO., LTD. (CN) 2023-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230008368-A1 IMIDAZOQUINOLINE SUBSTITUTED PHOSPHORIC ESTER AGONIST, AND PREPARATION THEREFOR AND APPLICATION THEREOF TLR4, TLR7, TLR1 KDM4E 2733/4885ALDH1A1 2873/4885RAB9A 3624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.